biguanides has been researched along with Glial Cell Tumors in 4 studies
Biguanides: Derivatives of biguanide (the structure formula HN(C(NH)NH2)2) that are primarily used as oral HYPOGLYCEMIC AGENTS for the treatment of DIABETES MELLITUS, TYPE 2 and PREDIABETES.
biguanides : A class of oral hypoglycemic drugs used for diabetes mellitus or prediabetes treatment. They have a structure based on the 2-carbamimidoylguanidine skeleton.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The pharmacological characteristics of 5-HT3 receptor (5-hydroxytryptamine3 receptor) recognition sites labelled with [3H]-(S)-zacopride and [3H]granisetron in membranes prepared from NG108-15 neuroblastoma-glioma cells were directly compared to investigate further differences in the binding characteristics of these two radioligands." | 7.68 | Differential binding characteristics of agonists at 5-HT3 receptor recognition sites in NG108-15 neuroblastoma-glioma cells labelled by [3H]-(S)-zacopride and [3H]granisetron. ( Barnes, JM; Barnes, NM, 1993) |
| "The pharmacological characteristics of 5-HT3 receptor (5-hydroxytryptamine3 receptor) recognition sites labelled with [3H]-(S)-zacopride and [3H]granisetron in membranes prepared from NG108-15 neuroblastoma-glioma cells were directly compared to investigate further differences in the binding characteristics of these two radioligands." | 3.68 | Differential binding characteristics of agonists at 5-HT3 receptor recognition sites in NG108-15 neuroblastoma-glioma cells labelled by [3H]-(S)-zacopride and [3H]granisetron. ( Barnes, JM; Barnes, NM, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (75.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barbieri, F | 1 |
| Bosio, AG | 1 |
| Pattarozzi, A | 1 |
| Tonelli, M | 1 |
| Bajetto, A | 1 |
| Verduci, I | 1 |
| Cianci, F | 1 |
| Cannavale, G | 1 |
| Palloni, LMG | 1 |
| Francesconi, V | 1 |
| Thellung, S | 1 |
| Fiaschi, P | 1 |
| Mazzetti, S | 1 |
| Schenone, S | 1 |
| Balboni, B | 1 |
| Girotto, S | 1 |
| Malatesta, P | 1 |
| Daga, A | 1 |
| Zona, G | 1 |
| Mazzanti, M | 1 |
| Florio, T | 1 |
| Barnes, JM | 1 |
| Barnes, NM | 1 |
| Rondé, P | 1 |
| Nichols, RA | 1 |
| Boess, FG | 1 |
| Sepúlveda, MI | 1 |
| Lummis, SC | 1 |
| Martin, IL | 1 |
4 other studies available for biguanides and Glial Cell Tumors
| Article | Year |
|---|---|
Chloride intracellular channel 1 activity is not required for glioblastoma development but its inhibition dictates glioma stem cell responsivity to novel biguanide derivatives.
Topics: Biguanides; Cell Line, Tumor; Chloride Channels; Glioblastoma; Glioma; Humans; Neoplastic Stem Cells | 2022 |
Differential binding characteristics of agonists at 5-HT3 receptor recognition sites in NG108-15 neuroblastoma-glioma cells labelled by [3H]-(S)-zacopride and [3H]granisetron.
Topics: Animals; Benzamides; Biguanides; Binding Sites; Binding, Competitive; Bridged Bicyclo Compounds; Bri | 1993 |
High calcium permeability of serotonin 5-HT3 receptors on presynaptic nerve terminals from rat striatum.
Topics: Animals; Biguanides; Calcium; Calcium Channel Blockers; Calcium Channels; Cell Membrane Permeability | 1998 |
5-HT3 receptors in NG108-15 neuroblastoma x glioma cells: effect of the novel agonist 1-(m-chlorophenyl)-biguanide.
Topics: Animals; Biguanides; Binding, Competitive; Evoked Potentials; Glioma; Hybrid Cells; Imidazoles; Indo | 1992 |